News

MyChesCo on MSN44m

Kite to Buy Interius BioTherapeutics for $350 Million, Advancing In Vivo CAR T Strategy

Kite, a Gilead company (Nasdaq: GILD), has agreed to acquire Interius BioTherapeutics for $350 million in cash, a move aimed at bringing in ...